The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
Final guidance published today (Thursday 4 December 2025) conditionally recommends seven digital technologies that can support cardiac rehabilitation for adults with cardiovascular disease in the NHS.
Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334] None selected Awaiting decision 19 November 2025 Donanemab for reducing the risk of mild cognitive impairment in preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results